Applied Filters
A global approach: Novo Nordisk's IP strategy
While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.
Russia v Eurasia: national and regional differences in patentability
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.
Biotech threats in the SPC system
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.
Post-grant patent challenges in Europe and the US: harmony at last?
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.
The European take on the Bolar provision: conclusions from Astellas v Polpharma
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.
Twenty-one years of SPCs – a cause for celebration?
Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.
The likely role of the UPC in pharma patent litigation
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.
Hub and spoke? Life sciences in Northern France
It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more.
A changing landscape: life sciences in Russia
Russia’s life sciences industry is growing rapidly, say Vadim Chagin and Maria Nilova.
Formal obligations: burdens on biotech patents
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
